Revelation Biosciences, Inc. (REVB)
Chart Events
Performance Outlook
| Previous Close | 0.2850 |
| Open | 0.2883 |
| Bid | 0.2900 x 1300 |
| Ask | 0.3000 x 1200 |
| Day's Range | 0.2647 - 0.3255 |
| 52 Week Range | 0.1690 - 2.8800 |
| Volume | |
| Avg. Volume | 488,681 |
| Market Cap | 7.061M |
| Beta (5Y Monthly) | -0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.7300 |
| Earnings Date | Nov 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for REVB
Related Research
- Revelation Biosciences, Inc.Daily – Vickers Top Buyers & Sellers for 02/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Business Wire
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
SAN DIEGO, January 31, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 30, 2023. The reverse stock split will be effective as of the morning of February 1, 2023, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under t
- Business Wire
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
SAN DIEGO, January 10, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on January 13, 2023, the Company’s units, which trade with the ticker symbol "REVBU" will be mandatorily separated and the units will no longer trade on the Nasdaq Capital Market. Each unit is comprised of one share of the Company’s common stock and one warrant that entitles the holder to purchase one share of common stock at price of $11.50 per share. In the separation,
- Business Wire
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
SAN DIEGO, Calif., November 18, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that recently completed exploratory biomarker analysis has confirmed clinical development plans for REVTx-300 in the treatment of CKD and AKI. This new biomarker data is in addition to the previously-announced significant reduction in
